TME Pharma KOL Webinar: NOX-A12 Combination Therapies in First-Line Glioblastoma – The Key to the TME? Analysis of Maturing Data from the Ongoing GLORIA Trial
|DATE:||November 22, 2022|
|TIME:||12:00 PM EST|
About The Event
The webinar will feature a presentation from Frank A. Giordano, M.D. (Professor and Chair, Department of Radiation Oncology, University Medical Center Mannheim, Germany), who will present and discuss the latest top-line results of the GLORIA Phase 1/2 trial evaluating NOX-A12 in combination with radiotherapy (RT) ± bevacizumab in patients with newly diagnosed glioblastoma and unmethylated MGMT promoter. The data from the trial reported to date suggest a strong clinical benefit for the treatment of RT and escalating NOX-A12 dose levels with 90% of patients showing disease control and 40% reaching radiographic partial response (defined as ≥50% reduction in tumor size). The interim results disclosed in June 2022 from the triple combination of NOX-A12 + RT + bevacizumab suggested even deeper and more sustained responses with 100% of patients evaluable at the time achieving radiographic partial responses.
The webinar will follow Dr. Giordano’s poster presentation at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting that will take place on November 17-20, 2022, in Tampa, Florida, US. Dr. Giordano will discuss results from the GLORIA study, how they compare to the standard of care and what the investigators have learned from the therapy of patients treated with NOX-A12 + RT + bevacizumab.
NOX-A12 is an inhibitor of the chemokine CXCL12. It has been granted orphan drug status in the US and EU for the treatment of certain brain cancers and produced promising clinical data thus far. Dr. Giordano will be available for questions following the formal presentation.